Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Sir, Daptomycin resistance is unusual. We report a case of clinical and bacteriological failure in a patient with Enterococcus faecalis endocarditis treated with daptomycin and review available data on daptomycin resistance. A 53-year-old male was hospitalized for native mitral valve endocarditis due to methicillin-susceptible Staphylococcus aureus. Treatments with nafcillin and then vancomycin were discontinued due to a severe rash with both agents. Daptomycin was initiated followed by mitral valve replacement. The patient had a complicated, 2 month hospital course during which he developed a stage IV decubitus ulcer colonized with vancomycin-resistant E. faecalis. He completed 8 weeks of daptomycin at 6 mg/kg/day. One month after discharge, the patient was diagnosed with prosthetic mitral valve endocarditis caused by vancomycin-resistant E. faecalis. A transoesophageal echocardiogram showed multiple vegetations on the posterior leaflet of the mitral valve. Owing to penicillin allergy, treatment with daptomycin was initiated. Blood cultures on day 1 grew three different strains of E. faecalis, including a vancomycin-resistant daptomycin-susceptible E. faecalis (MIC >512 and 4 mg/L, respectively), a vancomycin-susceptible daptomycin-non-susceptible E. faecalis (MIC 2 and >8 mg/L, respectively), and a vancomycin-resistant daptomycin-non-susceptible E. faecalis (MIC >512 and >8 mg/L, respectively). Susceptibility testing was performed using MicroScan broth microdilution (Dade Behring Inc., West Sacramento, CA, USA). Daptomycin MICs were performed using Etest strips (AB Biodisk North America Inc., Piscataway, NJ, USA) on Mueller–Hinton plates and were confirmed at the CDC. Daptomycin susceptibility methods were supplemented with additional calcium, as recommended by the CLSI.1 Blood cultures on hospital days 2 and 4 again grew vancomycin-resistant, daptomycin-non-susceptible E. faecalis. Penicillin desensitization was attempted unsuccessfully. Linezolid was started on hospital day 7 and blood cultures cleared on day 9. Because he had heparin-induced thrombocytopenia, repeat valve replacement presented a high risk of stroke while on cardiac bypass. The patient therefore elected medical management. He was discharged on hospital day 16 on oral linezolid therapy for palliation. Ten days after discharge, bacteraemia returned. He elected hospice care and expired shortly thereafter. Antibacterial agents with activity against emerging multidrug-resistant Gram-positive pathogens are limited. Daptomycin is a novel cyclic lipopeptide that binds the cell membrane in a calcium-dependent fashion causing depolarization and release of intracellular ions with arrest in macromolecular synthesis and cell death.2 It is bactericidal against both susceptible and resistant Gram-positive organisms and has a low toxicity profile.2 However, it is not approved for use in vancomycin-resistant Enterococcus infections. Little is known about the potential emergence of daptomycin resistance among these species and there are no defined MIC breakpoints for a resistant category for Enterococcus according to the USA-FDA and CLSI. Case reports of clinical failures with daptomycin in S. aureus infections emerged shortly after approval.3 However, resistance among Enterococcus species has been reported in only seven published cases (Table 1).4–10 Currently, there are no studies on mechanisms of daptomycin resistance in enterococcal species. For S. aureus, changes in membrane structure and function correlate with in vivo development of daptomycin non-susceptibility,11,12 and mutations in proteins involved in cell permeability have been implicated in daptomycin MIC increases.13 Daptomycin, a large molecule, may get trapped in the cell wall, unable to bind its target in the cell membrane. Supporting this hypothesis, elevated daptomycin MICs have been found to correlate with decreased susceptibility to vancomycin in >90% of the S. aureus isolates,14 and the level of resistance for both drugs has been found to correlate positively with cell wall thickness in glycopeptide-intermediate S. aureus isolates.15 Daptomycin non-susceptible Enterococcus species isolates: case reports ESRD, end-stage renal disease; AML, acute myeloid leukaemia; DM, diabetes mellitus; HL, Hodgkin's lymphoma; CKD, chronic kidney disease; CHF, congestive heart failure; VR, vancomycin-resistant; PCN, penicillin; ref, reference; NR, not reported. Daptomycin non-susceptible Enterococcus species isolates: case reports ESRD, end-stage renal disease; AML, acute myeloid leukaemia; DM, diabetes mellitus; HL, Hodgkin's lymphoma; CKD, chronic kidney disease; CHF, congestive heart failure; VR, vancomycin-resistant; PCN, penicillin; ref, reference; NR, not reported. More recently, emergence of daptomycin heteroresistance was demonstrated for a vancomycin-heteroresistant E. faecium after exposure to vancomycin, suggesting the same underlying resistance mechanism.16 During therapy with daptomycin
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although >90% of enterococci are reportedly susceptible in vitro to daptomycin, the emergence of daptomycin resistance is an increasing problem.207”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
Cui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Edelstein, M., Pimkin, M., Palagin, I., Edelstein, I., & Stratchounski, L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3724-3732.2003 · Cited by 404
Daptomycin‐Resistant, Methicillin‐Resistant Staphylococcus aureus Bacteremia
Mangili, A., Bica, I., Snydman, D. R., & Hamer, D. H. (2005) · Clinical Infectious Diseases · doi:10.1086/428616 · Cited by 256
Resistance Studies with Daptomycin
Silverman, J. A., Oliver, N., Andrew, T., & Li, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1799-1802.2001 · Cited by 234
Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy
Sabol, K., Patterson, J. E., Lewis, J. S., Owens, A., Cadena, J., & Jorgensen, J. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1664-1665.2005 · Cited by 209
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Gould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
A Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Dale, J. L., Cagnazzo, J., Phan, C. Q., Barnes, A. M. T., & Dunny, G. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00344-15 · Cited by 147
Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians
Kelesidis, T., Humphries, R., Uslan, D. Z., & Pegues, D. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq113 · Cited by 146
Revest, M., Camou, F., Senneville, E., Caillon, J., Laurent, F. J., Calvet, B., Feugier, P., Batt, M., & Chidiac, C. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.04.014 · Cited by 124
KRINKO (2018) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-018-2811-2 · Cited by 118
Hossion, A. M. L., Zamami, Y., Kandahary, R. K., Tsuchiya, T., Ogawa, W., Iwado, A., & Sasaki, K. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200010x · Cited by 100
A potential role for daptomycin in enterococcal infections: what is the evidence?
Canton, R., Ruiz-Garbajosa, P., Chaves, R. L., & Johnson, A. P. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq087 · Cited by 94
Zhang, H., Fouts, D. E., DePew, J., & Stevens, R. H. (2013) · Microbiology · doi:10.1099/mic.0.067116-0 · Cited by 90
Daptomycin: evaluation of a high-dose treatment strategy
Wu, G. D., Abraham, T., Rapp, J. A., Vastey, F., Saad, N., & Balmir, E. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.03.006 · Cited by 65
Daptomycin: pharmacology and clinical use
Kosmidis, C., & Levine, D. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003598893 · Cited by 57
Future directions with daptomycin
Livermore, D. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn371 · Cited by 51
Torelli, R., Cacaci, M., Papi, M., Sterbini, F. P., Martini, C., Posteraro, B., Palmieri, V., Spirito, M. D., Sanguinetti, M., & Bugli, F. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.07.010 · Cited by 45
Implications of the expression of Enterococcus faecalis citrate fermentation genes during infection
Martino, G. P., Pérez, C., Magni, C., & Blancato, V. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205787 · Cited by 31
Daptomycin: Physicochemical, Analytical, and Pharmacological Properties
Tótoli, E. G., Garg, S., & Salgado, H. R. N. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000222 · Cited by 26
Hossion, A. M. L., Otsuka, N., Kandahary, R. K., Tsuchiya, T., Ogawa, W., Iwado, A., Zamami, Y., & Sasaki, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.060 · Cited by 24
Vancomycin resistance: are there better glycopeptides coming?
Linden, P. K. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.917 · Cited by 23
Rathe, M., Kristensen, L., Ellermann‐Eriksen, S., Thomsen, M. K., & Schumacher, H. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02559.x · Cited by 22
Sawada, H., Okazaki, M., Morita, D., Kuroda, T., Matsuno, K., Hashimoto, Y., & Miyachi, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.052 · Cited by 18
Daptomycin in endocarditis and bacteraemia: a British perspective
Warren, R. E. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn370 · Cited by 18
Legout, L., D’Elia, P., Sarraz-Bournet, B., Ettahar, N., Haulon, S., Leroy, O., & Senneville, E. (2014) · Infectious Diseases and Therapy · doi:10.1007/s40121-014-0035-9 · Cited by 10
McCarthy, M. W., Baker, T., Satlin, M. J., & Walsh, T. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-77674-3_15 · Cited by 7
Sharma, K., Sultana, T., Liao, M., Dahms, T. E. S., & Dillon, J. R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00083 · Cited by 6
Madasani, S., Devineni, S. R., Chamarthi, N. R., Pavuluri, C. M., Vejendla, A., & Venkataramaiah, C. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2110905 · Cited by 5
Bashore, T. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5892-2.00022-2 · Cited by 5
Bashore, T. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4860-0.00025-6 · Cited by 4
Ummadi, R. R., Ratnakaram, V. N., Devineni, S. R., Subramanyam, C., & Singh, H. (2025) · Chemical Papers · doi:10.1007/s11696-025-04533-3 · Cited by 1
Kelesidis, T. (2014) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s9283 · Cited by 1
Exploring the Coenzyme A Biosynthetic Pathway as Novel Antibiotic Target.
Yao, J. (2010) · Deep Blue (University of Michigan) · Cited by 1
Clinical Aspects of Multi-Drug Resistant Enterococci
Contreras, G., & Arias, C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1400-1_19
The Role of Antibiotic Policies in Controlling VRE
Bal, A. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1734-8_7
Updated Antimicrobial Therapy for the Prevention and Treatment of Endocarditis: Focus on Daptomycin
González-Ruiz, A., & Jones, A. M. (2012) · Infectious Diseases Research and Treatment · doi:10.4137/idrt.s7579
Sharma, K. (2020) · HARVEST (University of Saskatchewan)
Manrique, J. C. R. (2020) · Repositorio Institucional (Pontificia Universidad Javeriana) · doi:10.11144/javeriana.10554.15427
Metadata
- Authors
- Hidron, A. I., Schuetz, A. N., Nolte, F. S., Gould, C. V., & Osborn, M. K.
- Affiliations
- Emory University (US)
- Medical University of South Carolina (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Osborn, M. K.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-13
- Volume
- 61
- Issue
- 6
- Pages
- 1394-1396
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2104855799
- Cited by
- 35
- References
- 22
- Citations by year
- 2025: 1 · 2022: 1 · 2020: 3 · 2018: 3 · 2017: 1 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- daptomycin resistance, Enterococcus faecalis, prosthetic valve endocarditis, vancomycin resistance, methicillin-susceptible Staphylococcus aureus, penicillin allergy, linezolid, heparin-induced thrombocytopenia, mitral valve replacement, pressure ulcers, antimicrobial susceptibility testing
- MeSH terms
- Anti-Bacterial Agents, Endocarditis, Bacterial, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Enterococcus faecalis, Treatment Outcome, Daptomycin, Fatal Outcome, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.